As shown in the above results, Axl inhibition by R428 treatment significantly increased the percentage and absolute number of tumor-infiltrating cDCs (Figure 4B); this increase was predominantly derived from CD103+ cDCs when we further divided those cDC into two subsets of CD103+ and CD11b+ cells (Figure 5A). This evidence concerns the gene AXL and neoplasm.